Health, Safety and Biosafety Consultant, Dr Bishop Simon, will be presenting a free biosafety webinar in collaboration with the Institution of Occupational Safety and Health. This session offers insight into the controls used by safety professionals to protect our laboratory research scientist and the community around them, as they work to make the discoveries needed to advance the treatment of diseases.
News
Cambridge, UK, 14 June 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has appointed Dr Christian Dillon as Vice President of Biology. In this new role, Dr Dillon will work across all the Company’s areas of interest, including oncology, targeted protein degradation, and neurodegeneration, leading PhoreMost’s efforts to progress the novel targets identified by its SITESEEKER® platform towards drug discovery.
The next round of the Biomedical Catalyst will launch on 7th June. £18 Million is available to support industry-led research and development projects that seek to provide solutions to Health and Care challenges.
Air Products is pleased to announce that it has extended its agreement with One Nucleus for another two years. It means that One Nucleus members can benefit from preferential rates on liquid gases and associated equipment from Air Products until at least 2023.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER
Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).
Click here to view the June 2021 edition of eNews - an ON Helix preview.
Uppsala, Sweden June 7th 2021, - LINK Medical, a full-service contract research organization (CRO) providing product development and post-marketing services for the pharmaceutical and medical device industries, has signed a contract to join forces with Insife, an expert consulting and technology service provider for safety and pharmacovigilance organizations.
In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of